Amphastar P
$ 20.78
4.90%
07 Aug - close price
- Market Cap 873,481,000 USD
- Current Price $ 20.78
- High / Low $ 22.64 / 20.40
- Stock P/E 12.15
- Book Value 17.33
- EPS 1.63
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.10 %
- 52 Week High 31.26
- 52 Week Low 16.64
About
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Analyst Target Price
$22.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-27 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-08 |
| Reported EPS | 0.8 | 0.42 | 0.61 | 0.93 | 0.75 | 0.74 | 0.92 | 0.96 | 0.94 | 1.04 | 0.88 | 1.15 |
| Estimated EPS | 0.51 | 0.71 | 0.89 | 0.83 | 0.64 | 0.69 | 0.9383 | 0.98 | 0.75 | 0.79 | 0.91 | 0.69 |
| Surprise | 0.29 | -0.29 | -0.28 | 0.1 | 0.11 | 0.05 | -0.0183 | -0.02 | 0.19 | 0.25 | -0.03 | 0.46 |
| Surprise Percentage | 56.8627% | -40.8451% | -31.4607% | 12.0482% | 17.1875% | 7.2464% | -1.9503% | -2.0408% | 25.3333% | 31.6456% | -3.2967% | 66.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AMPH
2026-08-06 20:41:23
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported better-than-expected Q2 CY2026 results, with revenue of $183.9 million exceeding analyst estimates by 2% and non-GAAP profit of $0.91 per share significantly beating consensus estimates. The company achieved 5.4% year-on-year revenue growth and highlighted successful key goals including overall revenue growth, expansion of gross margins, new product launches, and advancement in its development pipelines. Despite a decrease in operating margin this quarter, the company's long-term performance shows solid compounded annual growth rates for sales and EPS.
2026-08-06 20:41:23
Amphastar Pharmaceuticals reported a 5% increase in Q2 2026 net revenues to $183.9 million, driven by growth in new products like Ipratropium bromide, despite declines in others such as BAQSIMI and Glucagon. The company achieved a gross margin expansion to 50.8%, although GAAP net income slightly decreased compared to the prior year. Amphastar also highlighted its robust pipeline, including several ANDA and biosimilar insulin candidates targeting markets exceeding $6.3 billion.
2026-08-06 19:40:29
Amphastar Pharmaceuticals, Inc. reported net revenues of $183.9 million for the second quarter of 2026, marking a 5% increase year-over-year. GAAP net income was $30.3 million ($0.67 per share), while adjusted non-GAAP net income reached $40.8 million ($0.91 per share). The company highlighted continued execution of its diversification strategy, including new product launches and advancement of its generic and proprietary pipelines.
2026-08-06 09:40:29
Pacer Advisors Inc. increased its stake in Amphastar Pharmaceuticals by 47.1% in the first quarter, purchasing 83,739 additional shares, bringing its total holdings to 261,483 shares valued at approximately $5.1 million. Despite this institutional interest, analyst sentiment remains cautious with a "Reduce" consensus rating and an average price target of $22, following Amphastar's recent quarterly earnings miss. The company's stock is trading near its 52-week low amidst these financial and analyst concerns.
2026-08-04 11:18:06
Amphastar Pharmaceuticals (NASDAQ: AMPH) is a biopharmaceutical company with a diverse product portfolio showing an 8.80% upside potential from its current stock price of $20.22, with an average target price of $22.00. Despite its strong free cash flow and return on equity, caution is advised due to an overbought RSI and cautious analyst sentiment with no buy ratings. The company's innovative product lineup and international expansion are key strengths for future growth.
2026-08-04 10:11:32
Dimensional Fund Advisors LP significantly increased its stake in Amphastar Pharmaceuticals (NASDAQ:AMPH) by 12.7% in the first quarter, now owning over 2 million shares. Despite this institutional interest, Amphastar's recent quarterly earnings missed analyst expectations for both EPS and revenue, contributing to a "Reduce" consensus rating from analysts with an average price target of $22. The stock recently opened at $20.22, with 65.09% of its shares held by institutional investors and hedge funds.
